Diversification is all well and good, but there's nothing wrong with a well-run company that does a few things very well. With an enviable franchise in multiple sclerosis, a promising pipeline and a host of pharmaceutical giants desperate for growth and operating leverage, Biogen Idec (Nasdaq:BIIB) could yet have a few surprises left for shareholders.

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

Steady Progress in Q3
Third quarter results did not have a lot of financial surprises, but Biogen Idec continues to grow nicely. Total revenue rose 11%, with Tysabri, which the company sells in partnership with Elan (NYSE:ELN), growing 26% and key drug Avonex showing 6% sales growth. Although Avonex seems to be showing some wear with Novartis's (NYSE:NVS) drug Gilenya on the market, it still represents over half of the company's sales.

Though the company saw some erosion in gross margin of more than one full point, it still stands at nearly 91%. Likewise, while reported operating income growth of 152% overstates real performance, adjusted operating income growth of 23% is hardly a poor or embarrassing result.

Tysabri not Done Yet
Tysabri has been a controversial and troublesome drug for Biogen Idec and Elan, for a while now. It shows remarkable efficacy in many patients, including those who have not had good responses to other MS treatments, but it carries a small, but real, risk of a very dangerous condition called progressive multifocal leukoencephalopathy.

This is not news; it has been an issue for nearly a decade now. What is news is that the company reached an agreement with Quest Diagnostics (NYSE:DGX), a few months ago, for a diagnostic test than can detect the JC virus antibody. The presence of the JC virus seems to correlate with the risk of PML; the availability of a reliable and safe diagnostic, should give doctors more confidence in prescribing Tysabri to their patients. That, in turn, should open up a large population of under-treated patients who could benefit from the drug and boost sales for this partnership.

A Strong Pipeline
Much of the enthusiasm for Biogen, today, centers around the two positive Phase three studies on BG-12, it's new oral MS drug. Though it will have to compete with Gilyena, as well drugs from Teva (Nasdaq:TEVA) and Merck (Nasdaq:MKGAY.PK), the safety and efficacy profile of BG-12 suggest a real potential winner here. At a minimum, BG-12 should ease the burden of flagging momentum in Avonex, while some believe that it could become a $3 billion drug, in its own right.

However, this is not a one-drug pipeline, by any means. Another promising MS drug is deeper in the pipeline; Biogen Idec shareholders can also look forward to late-stage trial data on compounds to treat ALS and hemophilia, later in 2012, neither of which seems to factor much in analyst models, at this point.

Time for Others to Come Knocking?
Assuming that BG-12 makes it to market and the launch goes reasonably well, it is hard to believe that Biogen Idec will be a public company other than by management's own choice. A company like Pfizer (NYSE:PFE), Merck (NYSE:MRK), or Sanofi (NYSE:SNY) would love to have that growing, profitable and cash-rich MS franchise for its own, to say nothing of the "call options" in BIIB's pipeline.

Now some investors may say that Biogen Idec is too expensive to take out. To be sure, the stock is not cheap by many metrics, and even less so when factoring in a presumed acquisition multiple. Here's the thing, Big Pharma hates doubt and is quite happy to pay up for certainty. In other words, paying for the near-certainty of Biogen Idec's compelling MS franchise, is more appealing than taking a flyer on a beaten-down oncology or autoimmune biotech with uncertain sales prospects. After all, remember that discount rates are a key part of valuation analyses and a lower discount rate, which accompanies greater certainty about a drug/company's prospects, can lead to a much higher "fair" price.

The Bottom Line
Buying Biogen Idec in hopes of a buyout is a risky endeavor and the stock is not cheap. Again, though, investors have to consider the certainty equation; stocks like Alexion (Nasdaq:ALXN) and Celgene (Nasdaq:CELG) aren't cheap either, but you know what you're getting. Accordingly, Biogen is at least a good hold, and may still be a credible buy, for those with longer horizons and less appetite for risk, relatively speaking. (For additional reading, take a look at A Checklist For Successful Medical Technology Investment.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing Stephen D. Simpson did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  2. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  3. Investing Basics

    How to Deduct Your Stock Losses

    Held onto a stock for too long? Selling at a loss is never ideal, but it is possible to minimize the damage. Here's how.
  4. Economics

    Is Wall Street Living in Denial?

    Will remaining calm and staying long present significant risks to your investment health?
  5. Stock Analysis

    When Will Dick's Sporting Goods Bounce Back? (DKS)

    Is DKS a bargain here?
  6. Investing News

    How AT&T Evolved into a Mobile Phone Giant

    A third of Americans use an AT&T mobile phone. How did it evolve from a state-sponsored monopoly, though antitrust and a technological revolution?
  7. Stock Analysis

    Home Depot: Can its Shares Continue Climbing?

    Home Depot has outperformed the market by a wide margin in the last 12 months. Is this sustainable?
  8. Stock Analysis

    Yelp: Can it Regain its Losses in 2016? (YELP)

    Yelp investors have had reason to be happy recently. Will the good spirits last?
  9. Stock Analysis

    Is Walmart's Rally Sustainable? (WMT)

    Walmart is enjoying a short-term rally. Is it sustainable? Is Amazon still a better bet?
  10. Stock Analysis

    GoPro's Stock: Can it Fall Much Further? (GPRO)

    As a company that primarily sells discretionary products, GoPro and its potential falls right in line with consumer trends. Is that good or bad?
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center